Fig. 7: SETD2 deficiency accelerates sphingomyelin accumulation and promotes the transition from PKD to ccRCC.
From: SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer
Schematic representing the role of SETD2 deficiency in promoting large-scale metabolic reprogramming and sphingomyelin biosynthesis during PKD-ccRCC transition.
